Helper-dependent adenoviral vector achieves prolonged, stable expression of interleukin-10 in rabbit carotid arteries but does not limit early atherogenesis

Human Gene Therapy

Volumn 22, Issue 8, 2011, Pages 959-968

  Du, Liang ^a   Dronadula, Nagadhara ^a   Tanaka, Shinji ^a   Dichek, David A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHOLESTEROL; GAMMA INTERFERON; HELPER DEPENDENT ADENOVIRUS VECTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CELL COUNT; CARDIOVASCULAR GENE THERAPY; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; EXPERIMENTAL MODEL; EXPERIMENTAL RABBIT; GENE EXPRESSION; HEMATOCRIT; IMMUNOMODULATION; MACROPHAGE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; NULL ALLELE; OPTIMAL DRUG DOSE; PERIPHERAL BLOOD MONONUCLEAR CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME;

ADENOVIRIDAE; ANIMALS; ATHEROSCLEROSIS; CAROTID ARTERIES; GENE THERAPY; GENETIC VECTORS; HELPER VIRUSES; HUMANS; INTERLEUKIN-10; MALE; RABBITS;

ADENOVIRIDAE; ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 79957461678     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2010.175     Document Type: Article

References (47)

1. Aiuti, A., Cattaneo, F., Galimberti, S., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 447-458.
2. Akdis, C.A., and Blaser, K. (2001). Mechanisms of interleukin-10-mediated immune suppression. Immunology 103, 131-136. (Pubitemid 32521341)
3. Bhardwaj, S., Roy, H., and Ylä-Herttuala, S. (2008). Gene therapy to prevent occlusion of venous bypass grafts. Expert Rev. Cardiovasc Ther. 6, 641-652.
4. Booth, R.F.G., Martin, J.F., Honey, A.C., et al. (1989). Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis 76, 257-268. (Pubitemid 19101045)
5. Brunetti-Pierri, N., Stapleton, G.E., Law, M., et al. (2009). Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in non-human primates. Mol. Ther. 17, 327-333.
6. Chen, L., Anton, M., and Graham, F.L. (1996). Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat. Cell Mol. Genet. 22, 477-488. (Pubitemid 27194364)
7. Chen, Y.H., Chang, M., and Davidson, B.L. (2009). Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat. Med. 15, 1215-1218.
8. De Vries, J.E. (1995). Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann. Med. 27, 537-541.
9. Dronadula, N., Du, L., Flynn, R., et al. (2011). Construction of a novel expression cassette for increasing transgene expression in vivo in endothelial cells of large blood vessels. Gene Ther. [Epub ahead of print]; DOI: 10.1038/gt.2010.173.
10. Falkenberg, M., Tom, C., Deyoung, M.B., et al. (2002). Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc. Natl. Acad. Sci. U.S.A. 99, 10665-10670.
11. Feldman, L.J., Aguirre, L., Ziol, M., et al. (2000). Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. Circulation 101, 908-916. (Pubitemid 30117887)
12. Fichtlscherer, S., Breuer, S., Heeschen, C., et al. (2004). Inter-leukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J. Am. Coll. Cardiol. 44, 44-49. (Pubitemid 38968454)
13. Gersh, B.J., Sliwa, K., Mayosi, B.M., and Yusuf, S. (2010). Novel therapeutic concepts: The epidemic of cardiovascular disease in the developing world: Global implications. Eur. Heart J. 31, 642-648.
14. Gruchala, M., Bhardwaj, S., Pajusola, K., et al. (2004). Gene transfer into rabbit arteries with adeno-associated virus and adenovirus vectors. J. Gene Med. 6, 545-554. (Pubitemid 40228070)
15. Halvorsen, B., Waehre, T., Scholz, H., et al. (2005). Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. J. Lipid Res. 46, 211-219. (Pubitemid 40271084)
16. Han, X., Kitamoto, S., Lian, Q., and Boisvert, W.A. (2009). In-terleukin-10 facilitates both cholesterol uptake and efflux in macrophages. J. Biol. Chem. 284, 32950-32958.
17. Han, X., Kitamoto, S., Wang, H., and Boisvert, W.A. (2010). Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J. 24, 2869-2880.
18. Hippisley-Cox, J., and Coupland, C. (2010). Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. BMJ 340, c2197.
19. Kaul, S., Padgett, R.C., Waack, B.J., et al. (1992). Effect of atherosclerosis on responses of the perfused rabbit carotid artery to human platelets. Arterioscler. Thromb. 12, 1206-1213.
20. Kawashiri Ma, M., and Rader, D.J. (2000). Gene therapy for lipid disorders. Curr. Control Trials Cardiovasc. Med. 1, 120-127. (Pubitemid 32219892)
21. Liu, Y., Li, D., Chen, J., et al. (2006). Inhibition of atherogene-sis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis 188, 19-27. (Pubitemid 44160702)
22. Lloyd-Jones, D., Adams, R.J., Brown, T.M., et al. (2010). Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 121, e46-e215.
23. Lusis, A.J. (2000). Atherosclerosis. Nature 407, 233-241.
24. Mallat, Z., Besnard, S., Duriez, M., et al. (1999). Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85, e17-e24.
25. Mittereder, N., March, K.L., and Trapnell, B.C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498-7509. (Pubitemid 26339054)
26. Namiki, M., Kawashima, S., Yamashita, T., et al. (2004). Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 172, 21-29. (Pubitemid 38058597)
27. Newman, K.D., Dunn, P.F., Owens, J.W., et al. (1995). Adeno-virus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J. Clin. Invest. 96, 2955-2965.
28. Parks, R.J., Chen, L., Anton, M., et al. (1996). A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93, 13565-13570. (Pubitemid 26424159)
29. Perkins, H.D., Van Leeuwen, B.H., Hardy, C.M., and Kerr, P.J. (2000). The complete cDNA sequences of IL-2, IL-4, IL-6 AND IL-10 from the European rabbit (Oryctolagus cuniculus). Cyto-kine 12, 555-565. (Pubitemid 30453482)
30. Pinderski, L.J., Fischbein, M.P., Subbanagounder, G., et al. (2002). Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ. Res. 90, 1064-1071. (Pubitemid 34627904)
31. Pinderski Oslund, L.J., Hedrick, C.C., Olvera, T., et al. (1999). Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 19, 2847-2853. (Pubitemid 30029809)
32. Potteaux, S., Esposito, B., Van Oostrom, O., et al. (2004). Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 24, 1474-1478. (Pubitemid 39050443)
33. Rissanen, T.T., and Ylä-Herttuala, S. (2007). Current status of cardiovascular gene therapy. Mol. Ther. 15, 1233-1247. (Pubitemid 46965318)
34. Sandig, V., Youil, R., Bett, A.J., et al. (2000). Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc. Natl. Acad. Sci. U.S.A. 97, 1002-1007. (Pubitemid 30080802)
35. Schmittgen, T.D., and Livak, K.J. (2008). Analyzing real-time PCR data by the comparative CT method. Nat. Protoc. 3, 1101-1108. (Pubitemid 351818697)
36. Schneider, D.B., Vassalli, G., Wen, S., et al. (2000). Expression of Fas ligand in arteries of hypercholesterolemic rabbits accelerates atherosclerotic lesion formation. Arterioscler. Thromb. Vasc. Biol. 20, 298-308. (Pubitemid 30086084)
37. Schulick, A.H., Dong, G., Newman, K.D., et al. (1995). En-dothelium-specific in vivo gene transfer. Circ. Res. 77, 475-485.
38. Schulick, A.H., Taylor, A.J., Zuo, W., et al. (1998). Over-expression of transforming growth factor b1 in arterial endo-thelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc. Natl. Acad. Sci. U.S.A. 95, 6983-6988. (Pubitemid 28278093)
39. Smith, D.A., Irving, S.D., Sheldon, J., et al. (2001). Serum levels of the anti-inflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104, 746-749. (Pubitemid 32762668)
40. Suzuki, M., Cerullo, V., Bertin, T.K., et al. (2010). MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adeno-virus. Hum. Gene Ther. 21, 325-336.
41. Terkeltaub, R.A. (1999). IL-10: An "immunologic scalpel" for atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 19, 2823-2825.
42. Von Der Thusen, J.H., Kuiper, J., Fekkes, M.L., et al. (2001). Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/-mice. FASEB J. 15, 2730-2732.
43. Wen, S., Graf, S., Massey, P.G., and Dichek, D.A. (2004). Improved vascular gene transfer with a helper-dependent ade-noviral vector. Circulation 110, 1484-1491. (Pubitemid 39238028)
44. Wen, S., Schneider, D.B., Driscoll, R.M., et al. (2000). Second-generation adenoviral vectors do not prevent rapid loss of transgene expression and vector DNA from the arterial wall. Arterioscler. Thromb. Vasc. Biol. 20, 1452-1458. (Pubitemid 30353873)
45. White, K., Buning, H., Kritz, A., et al. (2008). Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther. 15, 443-451. (Pubitemid 351331002)
46. Ylä-Herttuala, S., and Martin, J.F. (2000). Cardiovascular gene therapy. Lancet 355, 213-222. (Pubitemid 30068227)
47. Yoshioka, T., Okada, T., Maeda, Y., et al. (2004). Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. Gene Ther. 11, 1772-1779. (Pubitemid 40028538)